60 completed, 4 unknown, 3 terminated, 2 recruiting. 72 Phase 2, 13 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 72 | Completed 60, Unknown 4, Terminated 3, Recruiting 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 13 | Completed 8, Terminated 3, Unknown 2 |
| Phase 3 | 6 | Completed 6 |
Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease RCI001 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye | Phase 2 | Not yet recruiting | Rudacure | 200 | 2027-09-01 | 2026-06-04 |
| Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment - Dry Eye, Eye Diseases | Phase 2 | Recruiting | University of Miami | 20 | 2026-07-21 | 2026-07-24 |
| Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease Ocular surface microbiota transplantation, placebo transplantation - Dry Eye | Phase 1 / Phase 2 | Completed | Second Affiliated Hospital of Nanchang University | 30 | 2025-12-26 | 2026-10-16 |
| An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye VSJ-110, Placebo - Dry Eye | Phase 2 | Recruiting | Vanda Pharmaceuticals | 160 | 2025-10-01 | 2025-09-17 |
| Phase 2b Controlled Study of Dosing Techniques - Part B IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Ophthalmic Eyelid Wipe 0.4% - Dry Eye | Phase 2 | Completed | IVIEW Therapeutics Inc. | 15 | 2025-09-08 | 2026-03-27 |
| Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye Tea Tree Oil Topical Application Oil, Azithromycin Ophthalmic Solution - Dry Eye | Phase 1 / Phase 2 | Completed | Ehab Mohamed Elsayed Mohamed Saad | 50 | 2025-03-01 | 2026-09-30 |
| Evaluation of BTV100 in Subjects With Dry Eye Disease BTV100 Low dose, BTV100 Mid dose, BTV100 High dose - Dry Eye | Phase 2 | Completed | BioTheraVision, Inc. | 123 | 2024-12-31 | 2026-10-07 |
| A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. TTAX03, Saline (NaCl 0,9 %) (placebo) - Dry Eye, Dry Eye Disease (DED) | Phase 2 | Completed | BioTissue Holdings, Inc | 74 | 2024-12-12 | 2026-02-11 |
| A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye VSJ-110, Placebo - Dry Eye | Phase 2 | Unknown | Vanda Pharmaceuticals | 40 | 2024-02-29 | 2024-03-06 |
| Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye Icross tear substitute, Hyabak tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 30 | 2023-11-01 | 2024-07-26 |
| Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 124 | 2023-07-01 | 2024-06-27 |
| OSIG-eye Drops Treatment for Dry Eye Disease Ocular Surface Immune Globulin (OSIG), Placebo - Dry Eye | Phase 2 | Withdrawn | University of Illinois at Chicago | 2023-05-15 | 2023-05-23 | |
| Study of OT202 in Treating Moderate to Severe Dry Eye OT202 conc 0.5%, OT202 conc 0.1%, Placebo - Dry Eye | Phase 2 | Completed | Ocumension Therapeutics (Shanghai) Co., Ltd | 213 | 2023-04-10 | 2024-05-30 |
| Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops - Dry Eye | Phase 2 | Completed | Johnson & Johnson Vision Care, Inc. | 121 | 2023-02-23 | 2025-04-27 |
| Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants 0.38% Sodium Hyaluronate (SH) Eye Drops, 0.18% Sodium Hyaluronate Eye Drops, Normal Saline Eye Drops - Dry Eye | Phase 2 | Completed | International Islamic University Malaysia | 45 | 2022-10-30 | 2025-03-03 |
| Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1) 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle) - Dry Eye | Phase 2 | Completed | Yuyu Pharma, Inc. | 257 | 2022-06-27 | 2024-07-30 |
| Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day - Dry Eye | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 141 | 2022-01-03 | 2026-03-03 |
| An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution) - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 56 | 2021-09-09 | 2025-02-28 |
| A Clinical Trial to Assess Subjects With Dry Eye Disease. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 158 | 2021-06-15 | 2025-02-24 |
| Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease With Meibomian Gland Dysfunction taVNS, Hyaluronic acid eye drops - Dry Eye | Phase 1 / Phase 2 | Unknown | Beijing Tongren Hospital | 135 | 2021-06-01 | 2024-08-09 |
Showing 20 of 72. Sign in to see all of them.
Dry Eye Syndromes (72) · Sjogren's Syndrome (3) · Graft vs Host Disease (2) · Keratoconjunctivitis Sicca (2) · Meibomian Gland Dysfunction (2) · Xerophthalmia (2) · Arthritis, Rheumatoid (1) · Blepharitis (1) · Eye Diseases (1) · Keratitis (1) · Lupus Erythematosus, Systemic (1) · Meibomitis (1) · Scleroderma, Diffuse (1)
Lacrimal Apparatus Diseases (72) · Eye Diseases (71) · Immune System Diseases (4) · Arthritis (3) · Autoimmune Diseases (3) · Conjunctival Diseases (3) · Connective Tissue Diseases (3) · Eyelid Diseases (3) · Joint Diseases (3) · Mouth Diseases (3) · Musculoskeletal Diseases (3) · Rheumatic Diseases (3) · Salivary Gland Diseases (3) · Skin and Connective Tissue Diseases (3) · Stomatognathic Diseases (3)
Brimonidine Tartrate (2) · Carboxymethylcellulose Sodium (2) · Doxycycline (2) · Hyaluronic Acid (2) · Ophthalmic Solutions (2) · dornase alfa (2) · lifitegrast (2) · Aspirin (1) · BID protein, human (1) · Capsules (1) · Cyclosporins (1) · Deoxyribonucleases (1) · Dexamethasone (1) · Glycerol (1) · Hypromellose Derivatives (1)
Aldeyra Therapeutics, Inc. (4) · Santen Inc. (3) · University of Illinois at Chicago (3) · Alcon Research (2) · Laboratorios Sophia S.A de C.V. (2) · Novartis Pharmaceuticals (2) · Ocular Therapeutix, Inc. (2) · Sandeep Jain, MD (2) · Silk Technologies, Ltd. (2) · University of Miami (2) · University of Seville (2) · Vanda Pharmaceuticals (2) · Abbott Medical Optics (1) · Alacrity Biosciences, Inc. (1) · Alcon, a Novartis Company (1)
United States (46) · China (6) · Australia (2) · Canada (2) · Mexico (2) · Spain (2) · Taiwan (2) · Austria (1) · Chile (1) · Egypt (1) · Japan (1) · New Zealand (1) · Palestinian Territories (1)
Gail Torkildsen, MD (5) · Sandeep Jain, MD (5) · Anat Galor, MD, MSPH (1) · Cristhian A Urzua, MD (1) · Edmund K Waller, MD PhD (1) · Eric Donnenfeld, M.D. (1) · Eugene McLaurin, MD (1) · Gail L Torkildson, MD (1) · Giacomina Massaro Giordano, MD (1) · H. Jerome Crampton, MD (1) · Hui-Ju Lin, PhD (1) · Jamie Christensen (1) · Jay H. Mashburn (1)
PMID 11879137, PMID 17508121, PMID 18848318, PMID 20735287, PMID 22330307, PMID 22670856, PMID 23169882, PMID 24255046, PMID 25826322, PMID 28736340, PMID 28777385, PMID 31373862, PMID 33096271, PMID 33561944, PMID 35192105, PMID 36586669, PMID 37077305, PMID 37209594, PMID 37478969, PMID 38407974, PMID 39839752, PMID 42764009, PMID 42803882, PMID 9894935
R01EY024966 (1)